Drug intelligence / Profile preview

EP-00077

Development stage: Preclinical
Lead developer: Therorna
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

EP-00077 is a circular RNA (circRNA)-based therapeutic candidate under development by Yuanyin (Beijing) Biotechnology (also known as Therorna) for the treatment of systemic lupus erythematosus (SLE). Leveraging Therorna's proprietary circRNA platform, which utilizes splint-free enzymatic circularization and targeted lipid nanoparticle (LNP) delivery, EP-00077 is designed to provide stable and prolonged therapeutic protein expression in vivo. The program is currently in the discovery stage of development.

Beyond the preview

Go deeper on EP-00077.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-00077.